In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
(RTTNews) - Rapport Therapeutics, Inc. (RAPP), a clinical-stage biotechnology company focused on central nervous system disorders, on Thursday, announced promising results from its Phase 1 PET and MAD ...
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results